Date: 2013-03-19
Type of information: Collaboration agreement
Compound:
Company: Leo Pharma (Denmark) National Psoriasis Foundation (USA)
Therapeutic area: Autoimmune diseases - Dermatological diseases
Type agreement: collaboration
Action mechanism:
Disease: psoriasis
Details: "Leo Pharma wants to involve patients in shaping future care solutions,” says Kim Kjoeller, Senior Vice President Global Development, Leo Pharma. The danish pharmaceutical company has announced a co-creation agreement with the National Psoriasis Foundation (NPF) in the United States. This co-creation with NPF, which begins on 23 March, is based on the creation of Psoriasis Frontiers, a group of patients who will meet with Leo Pharma researchers during a series of workshops. The first task will be to consider patient needs in relation to new formulations, devices and packaging.
The Psoriasis Frontiers group will focus both on conventional pharmaceutical product innovation and on individualised care solutions such as patient engagement concepts, access models, diagnostic tools and digital technologies. Psoriasis Frontiers will act as a sounding board, working only with concepts and not with marketed products. Specific research findings will be subject to confidentiality; however partners are committed to publishing non-competitive findings to the general public.
The co-creation agreement with the US National Psoriasis Foundation aims to ensure that the needs of people suffering from psoriasis play a central role in the development of LEO Pharma’s future psoriasis care solutions. Ultimately, LEO Pharma hopes that its agreement with NPF will pave the way for improved care solutions that empower people to better manage their psoriasis.
Financial terms:
Latest news:
